(PharmaNewsWire.Com, January 13, 2017 ) Atrial fibrillation is one of the most common types of arrhythmia and is characterized by fast and irregular heart rhythms. The atria of patients suffering from the disease do not function properly. Atrial fibrillation can cause chest pain, heart failure, or stroke. The doctor needs to identify the first detected event of atrial fibrillation in a patient. The occurrence of two or more events of atrial fibrillation results in it being considered recurrent. In paroxysmal atrial fibrillation, the arrhythmia ends spontaneously, whereas in persistent atrial fibrillation the arrhythmia continues for more than a week.
Publisher's analysts forecast the global left atrial appendage closure market to grow at a CAGR of 33.54% during the period 2017-2021. For more information about this report: http://www.reportsweb.com/global-left-atrial-appendage-closure-market-2017-2021 . Covered in this report The report covers the present scenario and the growth prospects of the global left atrial appendage closure market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sale of medical devices required for left atrial appendage closure.
The market is divided into the following segments based on geography: -Americas -APAC -EMEA
Publisher's report, Global Left Atrial Appendage Closure Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors -AtriCure -Boston Scientific -Coherex Medical -St. Jude Medical
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
